立体定向放射外科联合抗PD-1+CTLA-4治疗、抗PD-1治疗、抗CTLA-4治疗、BRAF/MEK抑制剂、BRAF抑制剂或传统化疗治疗黑色素瘤脑转移
该研究纳入2011至2020年间257例1048个黑色素瘤脑转移病灶、共368次立体定向放射外科治疗的患者,比较不同全身治疗方案的疗效。结果显示抗PD-1+抗CTLA-4、抗PD-1及BRAF/MEK抑制剂较传统化疗改善远处颅内控制,各组局部控制无显著差异,12个月总生存率各组间差异显著。
要点
- 抗PD-1+抗CTLA-4、抗PD-1及BRAF/MEK抑制剂较传统化疗改善远处颅内控制。
- 各组局部控制无显著差异(p=0.78),放射性坏死率无显著差异(p=0.93)。
- 12个月总生存率各组差异显著(p<0.0001),抗PD-1+CTLA-4组为68%。
核心结论
- 这是评估立体定向放射外科联合多种全身治疗方案治疗黑色素瘤脑转移的最大系列研究之一。
- 分析发现不同全身治疗间总生存、远处黑色素瘤脑转移控制和系统性无进展生存存在显著差异。
- 局部控制和放射性坏死风险无差异。
研究设计与样本
- 研究纳入2011年至2020年间诊断为黑色素瘤脑转移并在接受抗PD-1+CTLA-4治疗、抗PD-1治疗、抗CTLA-4治疗、BRAF/MEK抑制剂、BRAF抑制剂或传统化疗后3个月内接受立体定向放射外科治疗的患者。
- 共257例患者、1048个黑色素瘤脑转移病灶,接受368次立体定向放射外科治疗。
- 比较各组总生存、远处黑色素瘤脑转移控制、局部黑色素瘤脑转移、系统性无进展生存和神经毒性。
主要发现
- 多变量分析中,抗PD-1+抗CTLA-4、抗PD-1和BRAF/MEK抑制剂较传统化疗改善远处颅内控制。
- 各组局部控制无显著差异(p=0.78)。
- 12个月总生存率:抗PD-1+CTLA-4组68%、抗PD-1组59%、抗CTLA-4组45%、BRAF/MEK抑制剂组62%、BRAF抑制剂组21%、传统化疗组15%(p<0.0001)。
- 12个月系统性无进展生存率:抗PD-1+CTLA-4组57%、抗PD-1组53%、抗CTLA-4组42%、BRAF/MEK抑制剂组45%、BRAF抑制剂组14%、传统化疗组6%(p<0.0001)。
- 放射性坏死率无显著差异(p=0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immunotherapy and targeted BRAF/MEK inhibitors (i) have revolutionised the systemic management of advanced melanoma. Given the role of stereotactic radiosurgery (SRS) in the local management of brain metastases, we sought to evaluate clinical outcomes in patients with melanoma brain metastases (MBM) treated with SRS and various systemic therapies. METHODS: Patients were included if MBM were diagnosed and treated with SRS within 3 months of receiving anti-PD-1+CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK-i, BRAF-i, or conventional chemotherapy. Comparisons between groups were made for overall survival (OS), distant MBM control, local MBM, systemic progression-free survival (sPFS), and neurotoxicity. RESULTS: In total, 257 patients with 1048 MBM treated over 368 SRS sessions between 2011 and 2020 were identified. On MVA, treatment with anti-PD1+anti-CTLA-4, anti-PD-1, and BRAF/MEK-i improved distant intracranial control over conventional chemotherapy. No significant differences were noted in local control (LC) between groups (p = 0.78). Kaplan-Meier OS at 12 months for anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK-i, BRAF-i, and conventional chemotherapy was 68%, 59%, 45%, 62%, 21%, and 15%, respectively (p = <0.0001). The sPFS rates at 12 months were 57%, 53%, 42%, 45%, 14%, and 6% (p = <0.0001). No significant differences were noted in rates of radiation necrosis (p = 0.93). CONCLUSIONS: This is among the largest series evaluating MBM treated with SRS and various systemic therapy regimens. Our analysis noted significant differences in OS, distant MBM control, and sPFS by systemic therapy. No differences in LC or radiation necrosis risk were noted.
引用
- Dohm AE, Nakashima JY, Kalagotla H, et al. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer. 2023. PMID: 37657227. doi:10.1016/j.ejca.2023.113287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。